Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics
Open Access
- 15 January 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (2) , 671s-679s
Abstract
Recent advances in understanding the kidney cancer gene pathways has provided the foundation for the development of targeted therapeutic approaches for patients with this disease. Kidney cancer is not a single disease; it includes a number of different types of renal cancers, each with different histologic features, a different clinical course, a different response to therapy, and different genes causing the defects. Most of what is known about the genetic basis of kidney cancer has been learned from study of the inherited forms of kidney cancer: von Hippel Lindau (VHL gene), hereditary papillary renal carcinoma (c-Met gene), Birt Hogg Dubé (BHD gene), and hereditary leiomyomatosis renal cell cancer (fumarate hydratase gene). These Mendelian single-gene syndromes provide a unique opportunity to evaluate the effectiveness of agents that target the VHL, c-Met, BHD, and fumarate hydratase pathways.Keywords
This publication has 87 references indexed in Scilit:
- Distinct expression profile in fumarate-hydratase-deficient uterine fibroidsHuman Molecular Genetics, 2005
- Mechanisms and significance of bifunctional NK4 in cancer treatmentBiochemical and Biophysical Research Communications, 2005
- The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsOncogene, 2004
- The Genetic Basis of Cancer of the KidneyJournal of Urology, 2003
- Mutations in the Fumarate Hydratase Gene Cause Hereditary Leiomyomatosis and Renal Cell Cancer in Families in North AmericaThe American Journal of Human Genetics, 2003
- A novel germ line juxtamembrane Met mutation in human gastric cancerOncogene, 2000
- Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasOncogene, 2000
- MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMYJournal of Urology, 1999
- Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease PatientsThe American Journal of Pathology, 1998
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993